HBM Holdings Limited in 1 story
The narratives 2142.HK currently appears in, with its side and exposure in each.
Bull side
1 story- China Becomes Pharma's Global R&D Engine
2142.HK in “China Becomes Pharma's Global R&D Engine”
FadingExposure: not rated yetWestern drugmakers are licensing clinically validated Chinese molecules rather than relying solely on expensive in-house discovery.
Harbour BioMed's antibody-discovery platforms and China-developed immunology and oncology candidates create both licensing income and potential global clinical assets.
Bear side
0 storiesNo bear-side stories for 2142.HK yet.